Pharmaceutical - Par Pharmaceuticals


Current filters:

Par Pharmaceuticals

Popular Filters

US Appeals Court reverses 2012 decision on Lovaza, clearing way for generics


Reversing a district court decision last year (The Pharma Letter May 30, 2012), the US Court of Appeals…

AmarinCardio-vascularGenericsGlaxoSmithKlineLegalLovazaNorth AmericaPar PharmaceuticalsPatentsPharmaceuticalTeva Pharmaceutical IndustriesVascepa

Par Pharma challenges FDA authority on off-label promotion


In what may be a game-changer for drug companies, a court in the US District of Columbia has been asked…

Markets & MarketingMegace ESPar PharmaceuticalsPharmaceuticalRegulation

US antitrust body OKs Teva's acquisition of Cephalon, but with divestments


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US Federal Trade Commission…

CephalonGenericsLegalMergers & AcquisitionsNorth AmericaPar PharmaceuticalsPharmaceuticalProvigilTeva Pharmaceutical Industries

Avanir sues Par and Actavis over Nuedexta patent infringement


California, USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) has filed law suits in the US District Court…

ActavisAvanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPar PharmaceuticalsPatentsPharmaceutical

Back to top